MIRUM PHARMACEUTICALS

LIVMARLI is indicated for the treatment of cholestatic pruritus in patients who are 5 years of age and older with progressive familial intrahepatic cholestasis (PFIC)... Learn about LIVMARLI® for the treatment of cholestatic pruritus in patients ≥3 months of age with Alagille syndrome and ≥5 years of age with PFIC. LIVMARLI is not recommended in a subgroup of patients with PFIC type 2 with specific ABCB11 variants resulting in nonfunctional or complete absence of bile salt export pump-3 (BSEP-3) protein. May cause liver injury, GI problems, and fat-soluble vitamin deficiency. See full PI on website.

Also known as: Mirum Pharmaceuticals, Inc